| Literature DB >> 18631988 |
Abstract
In the absence of effective drugs for Alzheimer's disease (AD) and a validated roadmap or guideline for drug development, it is important to consider some of the limitations currently hampering AD drug development and some general principles for moving forward. This paper will address current barriers to developing drugs for AD, and offer new considerations for accelerating drug discovery, development, and clinical trials.Entities:
Mesh：
Year: 2007 PMID： 18631988 DOI： 10.1016/j.jalz.2007.11.005
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566